GE Healthcare is partnering with three organizations to improve cancer care: the University of Cambridge in the U.K., Optellum, and Sophia Genetics.
The three alliances are intended to help GE Healthcare support integrated health systems and medical professionals with diagnosis and treatment of cancer patients.
The University of Cambridge and Addenbrooke's Hospital plan to cooperate with GE on the development of an artificial intelligence (AI)-enhanced application that integrates cancer patient data from multiple sources into a single interface, according to a company statement.
GE and Optellum will help providers determine the malignancy of a lung nodule using AI. Optellum's Virtual Nodule Clinic identifies and scores the probability of malignancy, which may enable patients whose nodules are not malignant avoid unnecessary and aggressive procedures such as biopsy and surgical resection.
Sophia Genetics and GE will collaborate on various initiatives and projects, including advancing cancer care with the goal of better targeting and matching treatments to each patient's genomic profile and cancer type, helping to ensure the most effective and personalized treatment.
The two will initially work together on the creation of infrastructure to integrate data between GE's Edison platform and the Sophia DDM platform, as well as co-marketing and pilot site recruitment across oncology and radiogenomics.
